

**Table S10. Clinical variables and hematologic toxicity**

Characteristics	N	Hematologic toxicity		$\chi^2$	p-value	OR	IC <sub>95%</sub>
		NO N (%)	YES (Grade 1-4) N (%)				
<b>Gender</b>	101						
Female	52	50(96.2)	2(3.8)	-	1*	-	-
Male	49	48(98.0)	1(2.0)				
<b>Age diagnosis PS</b>	101	27.1 (18.0-44.3)	29.6 (24.2-34.3)	-	0.777	-	-
<b>Family History of Ps</b>	101						
Yes	52	49 (94.2)	3 (5.8)	-	0.243*	-	-
No	49	49 (100.0)	0 (0.0)				
<b>Smoking</b>	101						
Smoker	31	31 (100.0)	0 (0.0)	-	0.305*	-	-
Non-smoking	49	46 (93.9)	3 (6.1)				
Former Smoker	21	21 (100.0)	0 (0.0)				
<b>Alcoholic drinking</b>	101						
Drinker	38	38 (100.0)	0 (0.0)	-	0.325*	-	-
Non-drinker	61	58 (95.1)	3 (4.9)				
Former Drinker	2	2 (100.0)	0 (0.0)				
<b>Type of Psoriasis</b>	101						
Plaque	74	72(97.3)	2(2.7)	-	0.417*	-	-
Pustular	5	5(100.0)	0(0.0)				
Inverse	1	1(100.0)	0(0.0)				
Guttate	5	4(80.0)	1(20.0)				
Plaque and guttate	12	12(100.0)	0(0.0)				
Plaque and inverse	2	2(100.0)	0(0.0)				
Plaque and pustular	1	1(100.0)	0(0.0)				
Plaque, guttate and inverse	1	1(100.0)	1(0.0)				
<b>Localization</b>							
<b>Trunk and limbs</b>	101						
Yes	93	90(96.8)	3(3.2)	-	1*	-	-
No	8	8(100.0)	0(0.0)				
<b>Scalp and face</b>	101						
Yes	77	74(96.1)	3(3.9)	-	1*	-	-
No	24	24(100.0)	0(0.0)				
<b>Nails</b>	101						
Yes	58	56(96.6)	2(3.4)	-	1*	-	-
No	43	42(97.7)	1(2.3)				
<b>Palmoplantar</b>	101						
Yes	19	19(100.0)	0(0.0)	-	1*	-	-
No	82	79(96.3)	3(3.7)				
<b>Flexures</b>	101						
Yes	28	27 (96.4)	1 (3.6)	-	1*	-	-
No	73	71 (97.3)	2 (2.7)				
<b>Development of PSA</b>	101						
Yes	31	29(93.5)	2(6.5)	-	1*	-	-
No	70	69(98.6)	1(1.4)				
<b>Comorbidities</b>	101						

Yes	57	55(96.4)	2(3.5)	-	1*	-	-
No	44	43(97.7)	1(2.3)				
<b>Age of onset of MTX</b>	101	45.77±14.94	40.33±8.50	-	0.385	-	-
<b>MTX therapy duration (months)</b>	101	14.5 (5.0-35.3)	15.0 (8.5-19.5)	-	0.253	-	-
<b>MTX Administration</b>	101						
Oral	47	46 (97.9)	1 (2.1)	-	1*	-	-
Subcutaneous	30	29 (96.7)	1 (3.3)				
Both	24	23 (95.8)	1 (4.2)				
<b>Type of MTX therapy</b>	101						
Monotherapy	93	90 (96.8)	3 (3.2)	-	1*	-	-
Combination Therapy	8	8 (100.0)	0 (0.0)				
<b>Maximum MTX dose (mg/week)</b>	101	12.5 (10.-15.0)	15.0 (10.0-15.0)	-	0.756	-	-
<b>Therapeutic adherence</b>							
Adherent	70	68 (97.1)	2 (2.9)	-	1*	-	-
Intentional non-adherent	30	29 (96.7)	1 (3.3)				
Unintentional non-adherent	1	1 (100.0)	0 (0.0)				

\*p-value for the Fisher's test. PS: psoriasis; PSA: psoriatic arthritis